Eptinezumab-Jjmr
Common brands: Vyepti, Botox, Ubrelvy, Nurtec Odt, Topamax
Top reporter: Lundbeck Pharmaceuticals Llc
Calcitonin Gene-related Peptide Antagonist [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Calcitonin Gene-related Peptide Receptor Antagonist [EPC]Acetylcholine Release Inhibitor [EPC]Neuromuscular Blocker [EPC]
8,554
Total Reports
4,102
Serious Reports
55
Death Reports
30
Reported Reactions
Death Report Ratio: Low (0.64%)
Patient Demographics
Reported Adverse Reactions (30)
Side effects reported in FDA adverse event reports for Eptinezumab-Jjmr.
| # | Reaction | Reports | % of Total |
|---|---|---|---|
| 1 | DRUG INEFFECTIVE | 2,003 | |
| 2 | MIGRAINE | 1,413 | |
| 3 | HEADACHE | 927 | |
| 4 | THERAPEUTIC RESPONSE SHORTENED | 535 | |
| 5 | NAUSEA | 525 | |
| 6 | FATIGUE | 464 | |
| 7 | DRUG EFFECT LESS THAN EXPECTED | 349 | |
| 8 | THROAT IRRITATION | 336 | |
| 9 | DIZZINESS | 324 | |
| 10 | PRURITUS | 296 | |
| 11 | NASAL CONGESTION | 240 | |
| 12 | HYPERSENSITIVITY | 197 | |
| 13 | VOMITING | 195 | |
| 14 | DYSPNOEA | 189 | |
| 15 | MALAISE | 172 | |
| 16 | INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 159 | |
| 17 | CHEST DISCOMFORT | 155 | |
| 18 | COVID-19 | 153 | |
| 19 | COUGH | 150 | |
| 20 | RASH | 149 | |
| 21 | RHINORRHOEA | 135 | |
| 22 | OFF LABEL USE | 134 | |
| 23 | OROPHARYNGEAL PAIN | 129 | |
| 24 | ADVERSE DRUG REACTION | 128 | |
| 25 | THERAPEUTIC RESPONSE DECREASED | 126 | |
| 26 | FEELING ABNORMAL | 122 | |
| 27 | PAIN | 120 | |
| 28 | PRODUCT DOSE OMISSION ISSUE | 117 | |
| 29 | THERAPEUTIC RESPONSE DELAYED | 117 | |
| 30 | NASOPHARYNGITIS | 114 |
Important Disclaimer
FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.